OncoDaily Grand Rounds at ESMO 2026: Partners Unite for Sarcoma Research
HELEN-Trio 011: Camrelizumab Improves pCR With Anthracycline-Free Neoadjuvant Therapy in Stage II–III TNBC
Remembering Rachna Shroff: The Sunshine She Leaves Behind
Pat Garcia-Gonzalez at LeukO 2026: The CML Breakthrough That Still Hasn't Reached Everyone
Patrick Soon-Shiong: New Publication Highlights Durable Responses in Non-Muscle-Invasive Bladder Cancer
FURTHER: Firmonertinib Shows Promising Activity in EGFR PACC-Mutant Advanced NSCLC
Jay Bhattacharya: NIH FY2026 Shows Strong Investment in Research
Sanam Loghavi: Aplastic Anemia vs Hypocellular MDS, Solving Dameshek’s Riddle
OncoDaily IO is the dedicated immuno-oncology platform of OncoDaily, focused on the rapidly evolving science and clinical practice of cancer immunotherapy. It covers the full spectrum of immuno-oncology, including immune checkpoint blockade, cellular therapies, therapeutic cancer vaccines, antibody-based strategies, oncolytic viruses, next-generation immunomodulatory approaches, tumor microenvironment, immune biomarkers, neoantigens, treatment response and resistance, and personalized immunotherapy. Through OncoDaily IO, readers can follow the latest clinical trials, pivotal studies, translational research, regulatory decisions, emerging therapies, major congress highlights, and interviews with leading international experts advancing cancer prevention, control, and treatment through immunotherapy.
